The datasets showed a trend toward poorer overall survival (OS) in patients with low expression of IL33 than in patients with high expression in two out of three datasets ( S1 Fig ).
← all excerpts
Cancer cell-derived interleukin-33 decoy receptor sST2 enhances orthotopic tumor growth in a murine pancreatic cancer model.
1
—
—